» Articles » PMID: 2116973

Serotype-specific Outbreak of Group B Meningococcal Disease in Iquique, Chile

Overview
Date 1990 Aug 1
PMID 2116973
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

From 1979 to August 1987, there have been 178 cases of meningococcal disease in Iquique, Chile, a city of about 140,000. The attack rate for the last 5 years has been in excess of 20/100,000 per year, more than 20 times greater than for the country overall. The mortality rate was 6%. The disease occurred in patients with ages from 4 months to 60 years, but 89% of cases were in patients less than 21 years. The largest number of cases were in the age group 5-9 years (n = 54), but the highest incidence occurred in children less than 1 year of age (72.8/100,000 per year). The male/female ratio was 1.2. Cases occurred all year round with little seasonal variation. Of the 178 cases, 173 were biologically confirmed. Serogroup analysis of strains from 135 patients revealed A = 1, B = 124, C = 10. Forty-four group B strains from 1985-7 were serotyped: 15:P1.3 = 36, 15:NT = 4, 4:P1.3 = 2, NT:NT = 2. Ten of 11 of the outbreak strains tested were sulfadiazine-resistant. This is the first recognized outbreak caused by a Gp B:15 strain in South America. It shares many of the characteristics of outbreaks caused by closely related strains in Europe, such as a predilection for older children and adolescents, sulfadiazine-resistance, and sustained high attack rates. The Iquique strain (B:15:P1.3) belongs to the same genetic clone (ET-5 complex) as the Norway (B:15:P1.16) and the Cuban (B:4:P1.15) strains.

Citing Articles

Genomic Analysis of the Evolution and Global Spread of Hyper-invasive Meningococcal Lineage 5.

Harrison O, Bray J, Maiden M, Caugant D EBioMedicine. 2015; 2(3):234-243.

PMID: 25984558 PMC: 4430826. DOI: 10.1016/j.ebiom.2015.01.004.


Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.

Izquierdo G, Torres J, Santolaya M, Valenzuela M, Vega J, Chomali M Hum Vaccin Immunother. 2015; 11(4):875-83.

PMID: 25714390 PMC: 4514390. DOI: 10.1080/21645515.2015.1010885.


Clonal analysis of Neisseria meningitidis serogroup B strains in South Africa, 2002 to 2006: emergence of new clone ST-4240/6688.

Moodley C, du Plessis M, Ndlangisa K, de Gouveia L, Klugman K, von Gottberg A J Clin Microbiol. 2012; 50(11):3678-86.

PMID: 22972827 PMC: 3486271. DOI: 10.1128/JCM.01079-12.


The epidemiology of meningococcal disease in Latin America 1945-2010: an unpredictable and changing landscape.

Safadi M, Gonzalez-Ayala S, Jakel A, Wieffer H, Moreno C, Vyse A Epidemiol Infect. 2012; 141(3):447-58.

PMID: 22877581 PMC: 3566594. DOI: 10.1017/S0950268812001689.


The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology.

Racloz V, Luiz S BMC Infect Dis. 2010; 10:175.

PMID: 20565757 PMC: 2894839. DOI: 10.1186/1471-2334-10-175.


References
1.
Bennett J, CAMP H, Eickhoff T . Rapid sulfonamide disc sensitivity test for meningococci. Appl Microbiol. 1968; 16(7):1056-60. PMC: 547588. DOI: 10.1128/am.16.7.1056-1060.1968. View

2.
Garcia Moreno J, Prat Miranda M, VICENT P, Calderon B . [Serological evaluation of polyvalent A-C anti-meningococcal vaccine in Chile]. Bol Oficina Sanit Panam. 1982; 93(2):149-57. View

3.
Zollinger W, Moran E, Connelly H, Mandrell R, Brandt B . Monoclonal antibodies to serotype 2 and serotype 15 outer membrane proteins of Neisseria meningitidis and their use in serotyping. Infect Immun. 1984; 46(1):260-6. PMC: 261468. DOI: 10.1128/iai.46.1.260-266.1984. View

4.
Cartwright K, Stuart J, Noah N . An outbreak of meningococcal disease in Gloucestershire. Lancet. 1986; 2(8506):558-61. DOI: 10.1016/s0140-6736(86)90124-8. View

5.
Caugant D, Froholm L, BOVRE K, Holten E, Frasch C, Mocca L . Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc Natl Acad Sci U S A. 1986; 83(13):4927-31. PMC: 323857. DOI: 10.1073/pnas.83.13.4927. View